Some of the studies that reported NUCB1 and ANXA5 as up-regulated analyzed the effects of anti-lymphoma drug combinations, such as R-CHOP/CHOP regimens and immunomodulatory agents, on chemo-sensitive or -resistant DLBCL patients’ samples and DLBCL cell lines (Figure 3). This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.